Indegene share pros and cons: India’s only listed pharma digital health technology company at 40.47x PE with Big Pharma client stickiness analysed for 2026.

TCI Express share pros and cons: India’s leading B2B surface express logistics at approximately 32x PE with exceptional 22.97% ROE and manufacturing supply chain demand growth analysed for 2026.

Go Fashion share pros and cons: India’s leading women bottom-wear specialty retailer at approximately 65x PE with category creator moat and quality 20.18% ROE analysed for 2026.

Gland Pharma share pros and cons: India’s largest injectable pharma at 58.39x PE with Chinese parent Fosun ownership risk and US generic price erosion analysed for 2026.

Sun TV Network share pros and cons: South India’s dominant regional TV network at approximately 16x PE with extraordinary 40% ROE and OTT disruption risk analysed for 2026.

Suryoday Small Finance Bank share pros and cons: India’s smallest and cheapest listed SFB at 12.89x PE with micro-cap execution risk analysed for 2026.

Granules India share pros and cons: world’s 2nd-largest paracetamol API producer at reasonable PE with vertical integration advantage analysed for 2026.

Nazara Technologies share pros and cons: India’s only listed gaming and esports company at approximately 80x PE with WCC cricket game and Sportskeeda media platform analysed for 2026.

Inox Wind share pros and cons: India’s 2nd-largest wind turbine OEM at 24.68x PE with 3.2 GW order book and commissioning cycle volatility analysed for 2026.

HG Infra Engineering share pros and cons: Rajasthan roads EPC specialist at cheapest listed PE of approximately 12x with quality ROE and pan-India expansion analysed for 2026.